A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee
A Randomized, Double Blind, Three-arm, Parallel, Placebocontrolled, Clinical Study to Evaluate the Bioequivalence Using Clinical Endpoint of Diclofenac Sodium Gel, 1% (Mylan Inc.) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis Consumer Health, Inc.) in Patients With Osteoarthritis (OA) of the Knee
Sponsor: Mylan Pharmaceuticals Private Limited
A PHASE3 clinical study on Osteoarthritis, Knee, this trial is completed. The trial is conducted by Mylan Pharmaceuticals Private Limited and has accumulated 13 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Apr 2022 — Dec 2022 [monthly]
Completed PHASE3
-
May 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Jan 2021 — May 2021 [monthly]
Completed PHASE3
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE3
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mylan Pharmaceuticals Private Limited
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Bhubaneshwar, India , Chennai, India , Ernākulam, India , Himmatnagar, India , Hyderabad, India , Kolkata, India , Lucknow, India , Mangalore, India , Mumbai, India and 11 more locations